Adam Brickman's guest appearances

Adam Brickman

Navigating Neuropsychology

Simon Baron-Cohen

Bruce Miller

Emily Rogalski

Bob Bilder

Lisa Eyler

Keith Yeates

Jacobus Donders

Jeffrey Wozniak

Karen Postal

Tanya Nguyen

Beth Twamley

Neil Pliskin

Glenn Smith

Geoff Tremont

Meghan Collier

OwlTail

Adam Brickman, Ph.D., returns to discuss the involvement of white matter disease in Alzheimer’s disease progression and clinical presentation.  Dr. Brickman discusses his research on the presence of biomarkers of cerebrovascular disease (e.g., white matter hyperintensities), which are present in aging and Alzheimer’s disease. Although cerebrovascular disease is traditionally associated with its own unique cognitive profile, Dr. Brickman discusses evidence suggesting that the cognitive deficits and underlying etiologies often commingle and complicate our case conceptualization.  Additionally, he proposes the integral role that cerebrovascular disease may play in predicting (and possibly initiating) disease progression and cognitive decline in Alzheimer’s disease.   Show notes are available at www.NavNeuro.com/20 _____ If you’d like to support the show, here are a few easy ways: 1) Tell your friends and colleagues about it 2) Subscribe (free) and leave an iTunes review: www.NavNeuro.com/itunes 3) Contribute to the discussion in the comments section of the website (click the episode link listed above) or on Twitter (@NavNeuro)   Thanks for listening, and join us next time as we continue to navigate the brain and behavior!   [Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners’ own risk.  Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]

Adam Brickman, Ph.D., returns to discuss the involvement of white matter disease in Alzheimer’s disease progression and clinical presentation.  Dr. Brickman discusses his research on the presence of biomarkers of cerebrovascular disease (e.g., white matter hyperintensities), which are present in aging and Alzheimer’s disease. Although cerebrovascular disease is traditionally associated with its own unique cognitive profile, Dr. Brickman discusses evidence suggesting that the cognitive deficits and underlying etiologies often commingle and complicate our case conceptualization.  Additionally, he proposes the integral role that cerebrovascular disease may play in predicting (and possibly initiating) disease progression and cognitive decline in Alzheimer’s disease. Show notes are available at <a href="http://www.navneuro.com/20" rel="nofollow" target="_blank">www.NavNeuro.com/20</a> _____ If you’d like to support the show, here are a few easy ways: 1) Tell your friends and colleagues about it 2) Subscribe (free) and leave an iTunes review: <a href="http://www.navneuro.com/itunes" rel="nofollow" target="_blank">www.NavNeuro.com/itunes</a> 3) Contribute to the discussion in the comments section of the website (click the episode link listed above) or on Twitter (@NavNeuro) Thanks for listening, and join us next time as we continue to navigate the brain and behavior! [Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners’ own risk.  Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]

20| The Interplay Between Cerebrovascular Disease and Alzheimer’s Disease – With Dr. Adam Brickman

Despite global efforts to understand and ultimately assess, diagnose, and treat Alzheimer's disease (AD) more effectively, a consensus definition of AD still does not exist.  In 2018, the National Institute of Aging – Alzheimer’s Association (NIA-AA) Research Framework recommended that we should shift the definition of AD from a syndrome (i.e., the cognitive/behavioral symptoms that individuals present with) to a purely biological construct, specifically the presence of βamyloid deposition, pathologic tau, and neurodegeneration (the "A/T/N" model).  In this episode, we talk to Dr. Adam Brickman about the NIA-AA Research Framework biological definition of AD, the role of vascular contributions, assumptions about the amyloid hypothesis, and implications of not including the clinical syndrome in the diagnosis of AD. Show notes are available at www.NavNeuro.com/19 _____ If you’d like to support the show, here are a few easy ways: 1) Tell your friends and colleagues about it 2) Subscribe (free) and leave an iTunes review: www.NavNeuro.com/itunes 3) Contribute to the discussion in the comments section of the website (click the episode link listed above) or on Twitter (@NavNeuro)   Thanks for listening, and join us next time as we continue to navigate the brain and behavior!   [Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners’ own risk.  Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]

Despite global efforts to understand and ultimately assess, diagnose, and treat Alzheimer's disease (AD) more effectively, a consensus definition of AD still does not exist.  In 2018, the National Institute of Aging – Alzheimer’s Association (NIA-AA) Research Framework recommended that we should shift the definition of AD from a syndrome (i.e., the cognitive/behavioral symptoms that individuals present with) to a purely biological construct, specifically the presence of βamyloid deposition, pathologic tau, and neurodegeneration (the "A/T/N" model).  In this episode, we talk to Dr. Adam Brickman about the NIA-AA Research Framework biological definition of AD, the role of vascular contributions, assumptions about the amyloid hypothesis, and implications of not including the clinical syndrome in the diagnosis of AD. Show notes are available at <a href="http://www.navneuro.com/19" rel="nofollow" target="_blank">www.NavNeuro.com/19</a> _____ If you’d like to support the show, here are a few easy ways: 1) Tell your friends and colleagues about it 2) Subscribe (free) and leave an iTunes review: <a href="http://www.navneuro.com/itunes" rel="nofollow" target="_blank">www.NavNeuro.com/itunes</a> 3) Contribute to the discussion in the comments section of the website (click the episode link listed above) or on Twitter (@NavNeuro) Thanks for listening, and join us next time as we continue to navigate the brain and behavior! [Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners’ own risk.  Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]

19| Redefining Alzheimer's Disease: Does Cognition Matter? - With Dr. Adam Brickman